GlassScriptPhysician profile
Seth Banks
NPI 1588788301
$3,772.17
in general payments reported to CMS, 2019-2025
23 companies · $865 in 2025
The $865 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $15.48 · 2021: $141 · 2022: $350 · 2023: $800 · 2024: $864 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,529.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $942.27 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $449.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $393.53 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $316.82 | 2019-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $249.43 | 2019-2023 | Trulance, Xifaxan |
| Glaxosmithkline, LLC. | $242.83 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $223.56 | 2019-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $207.93 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $190.10 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $99.28 | 2019-2023 | Xarelto |
| Corcept Therapeutics | $87.09 | 2019-2025 | Korlym |
| Shield Therapeutics INC | $81.49 | 2023-2024 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.78 | 2019-2024 | Tradjenta, Jardiance |
| Kowa Pharmaceuticals America, INC. | $38.06 | 2019-2022 | |
| Ethicon INC. | $36.63 | 2024 | Monarch Platform |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $24.65 | 2019 | |
| Axsome Therapeutics, INC. | $24.30 | 2025 | Auvelity |
| Almatica Pharma LLC | $21.10 | 2021 | |
| Exact Sciences Corporation | $20.52 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $16.67 | 2022 | |
| Shire North American Group INC | $15.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.46 | 2019 | |
| Amarin Pharma, INC. | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Banks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.